Immtech Reports Fiscal Third Quarter 20...(ent under the Private Securities Reform ...),Health

Date:2/9/2009

ent under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech Pharmaceuticals, Inc.'s business which are not historical facts, are "forward-looking statements" that involve risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the headings "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in Immtech's annual report on Form 10-K for the year ended March 31, 2008 filed June 18, 2008, and in its other SEC filings and include, but are not limited to: (i) Immtech's ability to obtain additional funds; (ii) Immtech's ability to manage its remaining resources; (iii) Immtech's ability to continue as a going concern; (iv) Immtech's ability to retain key personnel; (v) the ability of Immtech's scientists and collaborators to discover new compounds; (vi) the availability of additional research grants; (vii) Immtech's ability to obtain regulatory approval of its drug candidates; (viii) the success of Immtech's clinical trials; (ix) dependence upon and contractual relationship with partners; (x) Immtech's ability to protect its intellectual property; and (xi) competition and alternative technologies.

In addition, Immtech does not undertake any obligation, and specifically disclaims any obligation to publicly update or revise forward-looking statements to reflect future events, information or circumstances that arise after the date of this release.

                           Immtech Pharmaceuticals, Inc.
                          Selected Financial Information
                                  (Unaudited)
                     (in thousands, except per share amounts)

                                                Three Months Ended
                                            
'/>"/>
SOURCE  Immtech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 
Related medicine news :

1. Immtech Announces Sale of Property Subsidiary in China
2. Immtech Receives Listing Notice From NYSE Alternext US
3. Immtech Reports Fiscal Second Quarter 2009 Results
4. Immtech Investor Conference Call Scheduled for June 25, 2008
5. Immtech Reports Fiscal Year End 2008 Results
6. Immtech Announces Results From Hepatitis C Discovery Program
7. Immtech Announces Update on Business Operations
8. Immtech Investor Conference Call Scheduled for February 22, 2008
9. Immtech Investor Conference Call Scheduled for January 3, 2008, at 1 PM
10. Immtech Announces Pafuramidine (DB289) Program on Clinical Hold
11. Immtech Completes Malaria Prevention Trial